JP6769982B2 - Ｒａｓ変異と関連するがんの治療方法 - Google Patents

Ｒａｓ変異と関連するがんの治療方法 Download PDF

Info

Publication number
JP6769982B2
JP6769982B2 JP2017546913A JP2017546913A JP6769982B2 JP 6769982 B2 JP6769982 B2 JP 6769982B2 JP 2017546913 A JP2017546913 A JP 2017546913A JP 2017546913 A JP2017546913 A JP 2017546913A JP 6769982 B2 JP6769982 B2 JP 6769982B2
Authority
JP
Japan
Prior art keywords
cancer
variant
protein
group
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507249A (ja
JP2018507249A5 (enExample
Inventor
ファン，ラン
Original Assignee
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56878960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6769982(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド, ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド filed Critical ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド
Publication of JP2018507249A publication Critical patent/JP2018507249A/ja
Publication of JP2018507249A5 publication Critical patent/JP2018507249A5/ja
Application granted granted Critical
Publication of JP6769982B2 publication Critical patent/JP6769982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017546913A 2015-03-06 2016-03-02 Ｒａｓ変異と関連するがんの治療方法 Active JP6769982B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562129654P 2015-03-06 2015-03-06
US62/129,654 2015-03-06
US201562249788P 2015-11-02 2015-11-02
US62/249,788 2015-11-02
PCT/US2016/020390 WO2016144635A1 (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation

Publications (3)

Publication Number Publication Date
JP2018507249A JP2018507249A (ja) 2018-03-15
JP2018507249A5 JP2018507249A5 (enExample) 2019-04-11
JP6769982B2 true JP6769982B2 (ja) 2020-10-14

Family

ID=56878960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546913A Active JP6769982B2 (ja) 2015-03-06 2016-03-02 Ｒａｓ変異と関連するがんの治療方法

Country Status (16)

Country Link
US (4) US10238650B2 (enExample)
EP (1) EP3265090A4 (enExample)
JP (1) JP6769982B2 (enExample)
KR (1) KR102626155B1 (enExample)
CN (1) CN107530341B (enExample)
AU (2) AU2016229294B2 (enExample)
BR (1) BR112017018954A2 (enExample)
CA (1) CA2978567A1 (enExample)
CL (1) CL2017002241A1 (enExample)
HK (1) HK1249052A1 (enExample)
IL (1) IL254256A0 (enExample)
MX (1) MX383691B (enExample)
MY (1) MY190034A (enExample)
RU (1) RU2736045C2 (enExample)
SG (2) SG11201707127VA (enExample)
WO (1) WO2016144635A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
JP2019019094A (ja) * 2017-07-19 2019-02-07 学校法人福岡大学 変異ｋｒａｓ関連シグナル阻害用組成物
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
KR20200112881A (ko) * 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
WO2019197605A2 (en) * 2018-04-12 2019-10-17 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
JP7500438B2 (ja) * 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
CN109652535A (zh) * 2019-01-30 2019-04-19 上海安甲生物科技有限公司 鉴别人甲状腺结节良恶性的试剂盒及其使用方法和应用
KR102222693B1 (ko) * 2019-04-04 2021-03-04 금정제약 주식회사 H-rev107 유래 펩타이드의 신규한 용도
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
US12121519B2 (en) 2019-11-28 2024-10-22 Inxmed (Nanjing) Co., Ltd. Use of BI853520 in cancer treatment
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
CN111534599A (zh) * 2020-06-18 2020-08-14 重庆浦洛通基因医学研究院有限公司 一种甲状腺癌辅助分子诊断试剂盒及使用方法
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
WO2023060200A1 (en) * 2021-10-07 2023-04-13 Beyondspring Pharmaceuticals, Inc. Methods for treating cancers and tumors
JP7823181B2 (ja) 2022-05-06 2026-03-03 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
EP4543438A1 (en) * 2022-06-26 2025-04-30 Biohaven Therapeutics Ltd. Methods of treating glioblastoma with prodrugs of riluzole
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN117919235A (zh) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 一种萘酰胺化合物治疗kras突变相关疾病的用途
WO2024088275A1 (zh) * 2022-10-25 2024-05-02 中国科学院上海药物研究所 一种萘酰胺化合物治疗耐药性肿瘤的用途
CN117942400A (zh) * 2022-10-31 2024-04-30 四川大学 Beclin 1抑制剂在制备治疗p53野生型癌症的药物中的用途
WO2024103010A1 (en) * 2022-11-11 2024-05-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
EP4719416A1 (en) * 2023-06-02 2026-04-08 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164B1 (enExample) 1970-12-29 1975-04-10
DE3061269D1 (en) 1979-06-29 1983-01-13 Wellcome Found Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
ZA818741B (en) 1980-12-18 1983-07-27 Wellcome Found Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation
JPS58167304A (ja) 1982-03-24 1983-10-03 松下電器産業株式会社 ごみ処理装置
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
DE69306545T2 (de) 1992-10-01 1997-04-03 Wellcome Found Tucaresol als Mittel zur Immunopotentierung
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
AU5612694A (en) 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
EP1032377B1 (en) 1997-11-21 2010-11-17 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
DE69940191D1 (de) 1998-01-29 2009-02-12 Aventis Pharma Inc VERFAHREN ZUR HERSTELLUNG EINER N-i(ALIPHATHISCH ODER AROMATISCH)CARBONYL -2-AMINOACETAMID-VERBINDUNG UND EINER CYCLISCHEN VERBINDUNG
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
BR9909146A (pt) 1998-03-26 2000-12-05 Shionogi & Co Derivados de indol apresentando uma atividade antiviral
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
KR100831400B1 (ko) 2000-01-18 2008-05-21 니리어스 파마슈티컬즈, 인크. 세포분열 저해제 및 그의 제조방법
WO2001070663A2 (en) 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
BR0110745A (pt) 2000-05-09 2003-12-30 Adpharma Inc Compostos de piperazinadiona
WO2002064592A1 (en) 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) * 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
BR0310026A (pt) 2002-05-17 2005-02-15 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ES2295695T3 (es) 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
AU2005212399B2 (en) 2004-02-04 2011-09-22 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EA010198B1 (ru) 2004-04-19 2008-06-30 Крка, Товарна Здравил, Д.Д., Ново Место Способы получения полиморфной формы i гидросульфата клопидогрела
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN103736086A (zh) 2007-02-15 2014-04-23 曼康公司 用于增强t细胞应答的方法
ES2389828T3 (es) 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
US20090170837A1 (en) * 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP2011509299A (ja) 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102378635A (zh) 2009-01-16 2012-03-14 特瓦制药工业有限公司 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
PT2464218E (pt) 2009-08-10 2015-09-16 Univ Texas Tratamento de metástases do cérebro com inibidores de recetores de endotelina, em combinação com um agente quimioterapêutico citotóxico
AU2010295646B2 (en) 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
EP2542699A4 (en) * 2010-03-03 2013-10-02 Targeted Molecular Diagnostics Llc METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
EP2576514A1 (en) 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20120214679A1 (en) 2010-11-29 2012-08-23 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2013078537A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
JP6647868B2 (ja) 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
AU2014244083B2 (en) 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
US10809323B2 (en) 2013-04-24 2020-10-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
TN2015000444A1 (en) 2013-06-03 2017-04-06 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
CA2926771C (en) 2013-10-11 2022-07-05 Beyondspring Pharmaceuticals, Inc. Cancer treatment with combination of plinabulin and taxane
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
ES2923942T3 (es) 2013-11-06 2022-10-03 Us Health Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
RU148945U1 (ru) 2014-07-29 2014-12-20 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) Конвективный блок водогрейного котла
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
CN117100753A (zh) 2015-02-12 2023-11-24 大连万春布林医药有限公司 普那布林联合免疫检查点抑制剂的用途
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物
US11174518B2 (en) 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
CA3056077A1 (en) 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
US20210030843A1 (en) 2018-02-01 2021-02-04 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
CN110240592A (zh) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
WO2019194738A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
JP7500438B2 (ja) 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
MX2021001762A (es) 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
JP2022513038A (ja) 2018-11-14 2022-02-07 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合薬を使用する癌の治療方法
CN112778155B (zh) 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
JP2023524530A (ja) 2020-05-04 2023-06-12 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法

Also Published As

Publication number Publication date
CN107530341A (zh) 2018-01-02
KR102626155B1 (ko) 2024-01-17
IL254256A0 (en) 2017-10-31
MX383691B (es) 2025-03-14
CN107530341B (zh) 2021-10-01
US10238650B2 (en) 2019-03-26
MY190034A (en) 2022-03-22
RU2017131430A3 (enExample) 2019-08-28
CA2978567A1 (en) 2016-09-15
US20190328727A1 (en) 2019-10-31
HK1249052A1 (zh) 2018-10-26
JP2018507249A (ja) 2018-03-15
RU2736045C2 (ru) 2020-11-11
CL2017002241A1 (es) 2018-04-02
US20180036304A1 (en) 2018-02-08
US20210275524A1 (en) 2021-09-09
US11918574B2 (en) 2024-03-05
AU2021290270A1 (en) 2022-01-27
AU2016229294A1 (en) 2017-09-28
SG11201707127VA (en) 2017-09-28
US20200289503A1 (en) 2020-09-17
EP3265090A4 (en) 2018-08-01
HK1250008A1 (zh) 2018-11-23
MX2017011374A (es) 2018-01-23
SG10202008673WA (en) 2020-10-29
US10668063B2 (en) 2020-06-02
AU2016229294B2 (en) 2021-11-04
BR112017018954A2 (pt) 2018-05-15
US11045467B2 (en) 2021-06-29
KR20170131491A (ko) 2017-11-29
EP3265090A1 (en) 2018-01-10
RU2017131430A (ru) 2019-04-09
WO2016144635A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
JP6769982B2 (ja) Ｒａｓ変異と関連するがんの治療方法
JP7264331B2 (ja) 脳腫瘍の治療方法
ES3060133T3 (en) Composition and method of treating cancer associated with egfr mutation
US9012458B2 (en) Antitumor agent using compounds having kinase inhibitory effect in combination
US20210113503A1 (en) Compositions and methods for treating cancer
JP2009502960A (ja) 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
CN119454695A (zh) Csf1r激酶抑制剂及其用途
AU2012308993A1 (en) Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
CN120676946A (zh) Debio-0123与替莫唑胺和放射治疗组合用于治疗胶质瘤
CN113521035B (zh) 化学免疫联合治疗纳米药物的制备方法及应用
CN108853114B (zh) 硝呋莫司在制备治疗癌症衍生的脑转移瘤的药物中的应用
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
JPWO2019138944A1 (ja) 細胞殺傷剤
WO2023016321A1 (zh) 恩沙替尼或其盐在治疗携带met 14外显子跳跃突变的疾病中的用途
HK1250008B (zh) 治疗与ras突变相关的癌症的方法
KR20250160958A (ko) 약학적 조합 및 이의 응용
EP2608793A1 (en) Use of a receptor-type kinase modulator for treating polycystic kidney disease
JP2022527532A (ja) メルフルフェンによるａｌアミロイドーシスの治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200924

R150 Certificate of patent or registration of utility model

Ref document number: 6769982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250